NCT06344416View on ClinicalTrials.gov

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

NARecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

January 30, 2026

Conditions

Any Solid Oral Medication

Interventions

DEVICE

Use of ReX to dispense and monitor solid oral medication therapy.

ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).

Trial Locations (4)

23229

RECRUITING

Virginia Cancer Center, Richmond

53717

RECRUITING

Lumicera, Madison

55407

RECRUITING

Allina, Minneapolis

78705

RECRUITING

Texas Oncology, Austin

All Listed Sponsors

lead

Dosentrx Ltd.

INDUSTRY

NCT06344416 - Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform | Biotech Hunter | Biotech Hunter